Target intelligence / Profile preview

Pre-mRNA-splicing factor SYF2 (SYF2)

Target: SYF2
Molecular classification: Other (splicing factor), Component of the spliceosome (RNA-protein complex involved in RNA processing), Member of the NTC complex / PRP19-associated complex, Nuclear protein

Overview

Pre-mRNA-splicing factor SYF2 is a highly conserved nuclear protein crucial for the pre-mRNA splicing process as part of the spliceosome, specifically the NTC/PRP19-associated complex. SYF2 regulates the cell cycle (particularly the G1/S transition) via interactions with cyclin D-type binding-protein 1 and is involved in DNA damage repair and splicing-dependent and independent mechanisms of gene expression control. Its dysregulation is associated with various cancers and is considered a potential oncogene and a candidate for targeted therapy and biomarker development, although no clinically approved drugs currently target SYF2 directly. Due to its essential role in fundamental processes of cell biology, therapeutic targeting of SYF2 must carefully consider safety concerns to avoid deleterious effects in normal cells.

Other names: CCNDBP1-interactorp29CBPINNTC31

Mechanism of action

Hypothetically, SYF2 knockdown or inhibition leads to cell cycle G1/S phase arrest and impaired cancer cell proliferation; modulation of splicing factor activity could alter oncogenic gene expression and disrupt tumor growth pathways.

Biological functions

Pre-mRNA splicingCell cycle regulation (especially G1/S phase transition)DNA damage repairRegulation of gene expressionInteraction with cell cycle and proliferation pathways, e.g., ECT2 oncogeneSplicing regulation including alternative splicing

Disease associations

Cancer (breast, gastric, ovarian, liver, esophageal, glioma)Tumor progression (as an oncogene and potential tumor marker)Intervertebral disc degenerationOther (may be involved broadly in disease development through cell cycle and gene expression regulation)

Safety considerations

Direct targeting of splicing factors like SYF2 may lead to off-target effects, impacting normal RNA processing and cell cycle control in healthy tissues.Potential for broad effects on gene expression, raising safety challenges (cytotoxicity, myelosuppression, impact on tissue homeostasis).As SYF2 is involved in fundamental cellular processes, inhibiting it risks widespread disruption of cell viability and function.

Interacting drugs

No specific drugs fully validated or listed in public databases; SYF2 is regarded as a prospective therapeutic target with candidate small molecule modulators under active research.

1 more in the full profile.

Biomarkers

SYF2 expression level is proposed as a novel tumor marker in various cancers, e.g., breast, gastric, ovarian, liver, and glioma.Its mRNA/protein expression patterns in tissues and disease states are researched as potential diagnostic, prognostic, or stratification biomarkers.

Beyond the preview

Go deeper on Pre-mRNA-splicing factor SYF2 (SYF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pre-mRNA-splicing factor SYF2 (SYF2).

Explore the full profile